HilleVax Q2 2025 net loss $11.3M; agrees to XOMA Royalty acquisition for $1.95/share + CVR

HilleVax, Inc.

Net loss of $11.3M for six months ended June 30, 2025, down from $87.5M in prior period.
Cash, cash equivalents and marketable securities totaling $159.5M as of June 30, 2025.
R&D expenses fell to $3.3M from $52.6M, driven by lower clinical development costs.
Definitive merger agreement: XOMA Royalty to buy all HLVX shares at $1.95 cash plus one CVR.
Tender offer to commence by August 18, 2025; closing expected in September 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.